ALX Oncology Holdings Inc header image

ALX Oncology Holdings Inc

ALXO

Equity

ISIN null / Valor 55754366

UTP NYSE Arca (2026-11-06)
USD 1.16+0.43%

ALX Oncology Holdings Inc
UMushroom community rating:

star star star star star
3.97 8 votes No rating yet
NegativeNeutralPositive

About company

ALX Oncology Holdings Inc is a publicly traded, clinical‑stage biotechnology company focused on developing immuno‑oncology therapies that modulate innate and adaptive immune checkpoints to enhance anti‑tumor responses. Its lead program is a CD47‑pathway targeted biologic designed to enable immune‑mediated clearance of cancer cells while minimizing hematologic toxicity, and the company advances this and other candidates in combination with checkpoint inhibitors and tumor‑directed antibodies across solid tumors and hematologic malignancies. ALX’s strategy centers on progressing these programs through clinical trials, pursuing regulatory approval pathways and strategic collaborations to commercialize therapies if clinical results support efficacy and safety.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-2.12%1Y
-87.1%3Y
-97.7%5Y

Performance

88.3%1Y
105%3Y
98.9%5Y

Volatility

Market cap

160 M

Market cap (USD)

Daily traded volume (Shares)

918,435

Daily traded volume (Shares)

1 day high/low

1.695 / 1.55

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

3.97

8 votes
Performance:
starstarstarstarstar
4.35
Innovation:
starstarstarstarstar
4.35
Society:
starstarstarstarstar
4.35
Nature:
starstarstarstarstar
4.35
basma chekkouri
France, 08 Nov 2026
star star star star star
good
Hanjun Jin
UK, 05 Nov 2026
star star star star star
Hopeful Stock
Ultima Thule
UK, 04 Nov 2026
star star star star star
momentum

EQUITIES OF THE SAME SECTOR

Biogen Inc
Biogen Inc Biogen Inc Valor: 1720684
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.81%USD 248.35
Zydus Lifesciences Limited
Zydus Lifesciences Limited Zydus Lifesciences Limited Valor: 29835501
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.12%INR 1,195.00
IPCA Laboratories Limited
IPCA Laboratories Limited IPCA Laboratories Limited Valor: 115718957
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.35%INR 1,942.95
AnaptysBio, Inc.
AnaptysBio, Inc. AnaptysBio, Inc. Valor: 29675116
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.91%USD 46.45
LeMaitre Vascular inc
LeMaitre Vascular inc LeMaitre Vascular inc Valor: 2755054
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.11%USD 80.89
GSK PLC
GSK PLC GSK PLC Valor: 120042705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.16%USD 50.33
Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited Valor: 3195888
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.32%INR 2,592.85
GSK PLC
GSK PLC GSK PLC Valor: 119642297
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%GBP 18.90
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC Valor: 2324471
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.77%GBP 16.50
Piramal Pharma Limited
Piramal Pharma Limited Piramal Pharma Limited Valor: 114197705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.17%INR 239.20